Brief Research Report

Accepted on 01 Dec 2023

Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients

in Skin Cancer

Lydia Warburton
Anna Reid
Benhur Amanuel
Leslie Calapre
Michael Millward
Elin Solomonovna Gray

Frontiers in Oncology

doi 10.3389/fonc.2023.1280730

Original Research

Published on 30 Nov 2023

Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma

in Skin Cancer

Charlotte Nübel
Teresa Amaral
Ulrike Leiter
Lukas Flatz
Andrea Forschner

Frontiers in Oncology

doi 10.3389/fonc.2023.1256800

263 views

Original Research

Accepted on 29 Nov 2023

Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation

in Skin Cancer

Silvia Alberti-Violetti
Marco Ardigo
Cesare Massone
Alessandro Pileri
Raffaella Sala
Miriam Teoli
Vieri Grandi
Pietro Quaglino
Nicola Pimpinelli
Emilio Berti

Frontiers in Oncology

doi 10.3389/fonc.2023.1298296

Case Report

Published on 24 Nov 2023

Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

in Skin Cancer

Katrin Pape
Maria Protopapa
Muriel Schraad
Falk Steffen
Frauke Zipp
Stefan Bittner

Frontiers in Oncology

doi 10.3389/fonc.2023.1303141

375 views

Brief Research Report

Accepted on 13 Nov 2023

Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas

in Skin Cancer

David R Minor
Kevin B Kim
Krishna Karuturi
Mohammed Kashani-Sabet

Frontiers in Oncology

doi 10.3389/fonc.2023.1241917

Original Research

Published on 08 Nov 2023

Cost items in melanoma patients by clinical characteristics and time from diagnosis

in Skin Cancer

Alessandra Buja
Claudia Cozzolino
Anna Zanovello
Ruggero Geppini
Andrea Miatton
Manuel Zorzi
Mariagiovanna Manfredi
Emanuela Bovo
Paolo Del Fiore
Saveria Tropea

Frontiers in Oncology

doi 10.3389/fonc.2023.1234931

390 views

Case Report

Accepted on 06 Nov 2023

Parsonage-Turner Syndrome in a Melanoma Patient Treated by BRAF/MEK Inhibitors after Immune Checkpoint Inhibitors

in Skin Cancer

Charlotte Bonnefin
Fanny Duval
Marie-France Rouanet
Marie Kostine
Emilie Gérard

Frontiers in Oncology

doi 10.3389/fonc.2023.1268693

Original Research

Published on 30 Oct 2023

A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and functional T cells

in Skin Cancer

Cheryl M. Cameron
Brian Richardson
Jackelyn B. Golden
Yee Peng Phoon
Banumathi Tamilselvan
Lukas Pfannenstiel
Samjhana Thapaliya
Gustavo Roversi
Xing-Huang Gao
Leah L. Zagore

Frontiers in Oncology

doi 10.3389/fonc.2023.1200387

509 views

Case Report

Published on 27 Oct 2023

Covid-19, leukemia, and secondary malignancies of the skin – is there a connection: a case report and literature analysis

in Skin Cancer

Olga Bogomolets
Ewa Rojczyk
Roman Hryshchenko
Catherine Bogomolets
Oleksandr Berezkin

Frontiers in Oncology

doi 10.3389/fonc.2023.1265479

983 views

Original Research

Published on 25 Oct 2023

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers

in Skin Cancer

Elvelyn R. Fernandez
Deborah Tamura
Sikandar G. Khan
Sophie Momen
Hiva Fassihi
Robert Sarkany
John J. DiGiovanna
Kenneth H. Kraemer

Frontiers in Oncology

doi 10.3389/fonc.2023.1282823

625 views

Original Research

Published on 23 Oct 2023

Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)

in Skin Cancer

David Russo
Stéphane Dalle
Olivier Dereure
Laurent Mortier
Sophie Dalac-Rat
Caroline Dutriaux
Marie-Thérèse Leccia
Delphine Legoupil
Henri Montaudié
Eve Maubec

Frontiers in Oncology

doi 10.3389/fonc.2023.1250026

671 views

Systematic Review

Published on 13 Oct 2023

Mapping the landscape of artificial intelligence in skin cancer research: a bibliometric analysis

in Skin Cancer

Qianwei Liu
Jie Zhang
Yanping Bai

Frontiers in Oncology

doi 10.3389/fonc.2023.1222426

811 views

Brief Research Report

Published on 05 Oct 2023

The utility of high-frequency 18 MHz ultrasonography for preoperative evaluation of acral melanoma thickness in Chinese patients

in Skin Cancer

Nianzhou Yu
Kai Huang
Yixin Li
Zixi Jiang
Siliang Liu
Yuancheng Liu
Xiaowan Liu
Zeyu Chen
Renliang He
Tianhong Wei

Frontiers in Oncology

doi 10.3389/fonc.2023.1185389

995 views

Editorial

Published on 28 Sep 2023

Editorial: The role of immunotherapy in melanomas

in Skin Cancer

Anna Fateeva
Suzie Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1293040

678 views

Case Report

Published on 20 Sep 2023

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma

in Skin Cancer

Karam Khaddour
Alice Zhou
Omar Butt
Jiayi Huang
George Ansstas

Frontiers in Oncology

doi 10.3389/fonc.2023.1276729

696 views

Brief Research Report

Published on 18 Sep 2023

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells

in Skin Cancer

Carlotta Guzzetti
Cristina Corno
Elisabetta Vergani
Luca Mirra
Emilio Ciusani
Monica Rodolfo
Paola Perego
Giovanni L. Beretta

Frontiers in Oncology

doi 10.3389/fonc.2023.1182853

716 views

Navigation group

Articles

Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients

Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma

Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation

Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas

Cost items in melanoma patients by clinical characteristics and time from diagnosis

Parsonage-Turner Syndrome in a Melanoma Patient Treated by BRAF/MEK Inhibitors after Immune Checkpoint Inhibitors

A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and functional T cells

Covid-19, leukemia, and secondary malignancies of the skin – is there a connection: a case report and literature analysis

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers

Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)

Mapping the landscape of artificial intelligence in skin cancer research: a bibliometric analysis

The utility of high-frequency 18 MHz ultrasonography for preoperative evaluation of acral melanoma thickness in Chinese patients

Editorial: The role of immunotherapy in melanomas

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells